The Research and Clinical Trials section provides information on topics related to the Duchenne research pipeline, varying treatment approaches, navigating clinical trials and more.
This webinar, hosted by CureDuchenne and Avidity Biosciences, presents the initial data from the EXPLORE 44 clinical trial. The trial evaluates the efficacy and safety of Dalzota (AOC 1044) for treating Duchenne muscular dystrophy (DMD) in patients amenable to exon 44 skipping. Key findings include a significant increase in exon skipping and dystrophin production, with a notable reduction in creatine kinase levels, indicating potential muscle health improvements. The discussion also covers the future plans for the trial and the urgency to advance treatment options for DMD patients.
This resource presents the innerworkings of the DMD gene, Duchenne’s impact on the body, and provides and in-depth view of the pipeline of current treatments for Duchenne.
We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you are agreeing to accept our use of cookies. For more information about cookies please visit our Privacy Policy page.I Agree
